Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Basic) (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed EPS (Basic) for 6 consecutive years, with -$168.03 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 13.35% year-over-year to -$168.03, compared with a TTM value of -$502.28 through Sep 2025, down 110.55%, and an annual FY2024 reading of -$366.33, down 50082.19% over the prior year.
  • EPS (Basic) was -$168.03 for Q3 2025 at Ovid Therapeutics, up from -$206.13 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $118.07 in Q2 2024 and bottomed at -$206.13 in Q2 2025.
  • Average EPS (Basic) over 5 years is -$38.97, with a median of -$0.21 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 65694.44% in 2024, while the deepest fall reached 121100.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.37 in 2021, then soared by 56.76% to -$0.16 in 2022, then tumbled by 31.25% to -$0.21 in 2023, then tumbled by 60842.86% to -$127.98 in 2024, then plummeted by 31.29% to -$168.03 in 2025.
  • Business Quant data shows EPS (Basic) for OVID at -$168.03 in Q3 2025, -$206.13 in Q2 2025, and -$0.14 in Q1 2025.